<DOC>
	<DOCNO>NCT02862457</DOCNO>
	<brief_summary>This open-label , non-randomized , Phase I study MK-3475 ( pembrolizumab ) INCB024360 ( epacadostat ) participant advance solid tumor . The primary objective trial evaluate safety tolerability INCB024360 administer alone combination MK-3475 .</brief_summary>
	<brief_title>Study INCB024360 Alone In Combination With Pembrolizumab ( MK-3475 ) Solid Tumors ( MK-3475-434 )</brief_title>
	<detailed_description />
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Has histologicallyconfirmed metastatic locally advanced solid tumor fail respond standard therapy , progress despite standard therapy , standard therapy exist . Has least one measurable lesion compute tomography magnetic resonance image per Response Evaluation Criteria In Solid Tumors ( RECIST ) 1.1 Has Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Has life expectancy ≥3 month Females must pregnant ( negative urine serum human chorionic gonadotropin test within 72 hour study start ) Women childbearing potential male participant must agree use adequate contraception study 120 day last dose study medication Has provide tissue program cell death ligand 1 ( PDL1 ) / Indoleamine 2,3dioxygenase 1 ( IDO1 ) expression evaluation archival tissue sample newly obtain core excisional biopsy tumor lesion previously irradiate Has receive prior therapy antiProgrammed cell death protein ( PD ) 1 , antiPDL1 , antiPDL2 , antiCD137 , antiCytotoxic Tlymphocyteassociated antigen4 ( CTLA4 ) agent ( include ipilimumab antibody/drug specifically target Tcell costimulation checkpoint pathway ) , IDO1 inhibitor Is currently participate participate study investigational compound device within 4 week , 5 time halflife investigational compound , whichever longer , initial dosing study Has chemotherapy , target small molecule therapy , radiotherapy , major surgery , biological cancer therapy ( include monoclonal antibody ) within 4 week ( 6 week nitrosoureas mitomycin C ) prior first dose study medication , recover ( ≤ Grade 1 baseline ) adverse event due previously administer treatment Is expect require form systemic localize antineoplastic therapy study Has active central nervous system ( CNS ) metastases and/or carcinomatous meningitis Has symptomatic ascites pleural effusion Has active autoimmune disease require systemic treatment Is receive systemic steroid therapy ( dose exceed 10 mg daily prednisone equivalent ) form immunosuppressive therapy within 1 week prior first dose study medication Has active infection require systemic therapy Has history evidence pneumonitis ( include radiation pneumonitis ) Has receive live vaccine within 4 week prior first dose study medication Has know hypersensitivity component trial treatment another monoclonal antibody Is Human Immunodeficiency Virus ( HIV ) positive ( HIV 1/2 antibody ) Has know history active Hepatitis B C Has know psychiatric substance abuse disorder would interfere cooperation requirement trial Is pregnant breastfeeding , expect conceive father child study 120 day last dose study medication Has receive monoamine oxidase inhibitor ( MAOIs ) within 3 week first dose study medication Has history Serotonin Syndrome receive serotonergic drug Has presence gastrointestinal condition may affect drug absorption</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced Solid Tumors</keyword>
</DOC>